Treatment of advanced prostate cancer.
Many patients with prostate cancer present with advanced disease (stage C or D). For these patients, treatment is palliative and is aimed at reducing serum testosterone levels. Since the growth of prostate cancer is testosterone-dependent (approximately 95% of testosterone is produced by the testes, with the remainder coming from the adrenals), hormonal manipulation has been the mainstay of palliative treatment. Bilateral orchiectomy has been the traditional approach, but most patients prefer equally effective drug therapies that include the administration of estrogens, luteinizing hormone-releasing hormone (LHRH) agonists, and anti-androgens.
Lynch
J H
JH
Division of Urology, Georgetown University Hospital, Washington, DC 20007.
D000726:Androgen Antagonists / Q000627:therapeutic use; D004967:Estrogens / Q000627:therapeutic use; D007987:Gonadotropin-Releasing Hormone / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000188:drug therapy*
D000726:Androgen Antagonists; D004967:Estrogens; D007987:Gonadotropin-Releasing Hormone